Read a great synopsis of 2016 AD research developments in the Alzheimer’s Forum’s—A Year in Research by Tom Fagan and Gabrielle Strobel
No use soft-pedaling a hard truth: The year ended on a downer. Solanezumab—the therapeutic antibody in line to be the first approved AD drug in well over a decade—failed to significantly slow cognitive decline in people with mild AD and a positive amyloid scan/CSF Aβ profile.